Caris Life Sciences, Inc. (CAI) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Caris Life Sciences, Inc. (CAI:NASDAQ), powered by AI.

Current Price
$17.97
P/E Ratio
-44.1
Market Cap
3.0B
Sector
Healthcare
What is the Caris Life Sciences, Inc. stock price forecast?

Caris Life Sciences, Inc. is currently trading at $17.97. View real-time AI analysis on Alpha Lenz.

What is Caris Life Sciences, Inc. insider trading activity?

View the latest insider trading data for Caris Life Sciences, Inc. on Alpha Lenz.

What is Caris Life Sciences, Inc.'s P/E ratio?

Caris Life Sciences, Inc.'s P/E ratio is -44.1.

Caris Life Sciences, Inc.

NASDAQ · CAI
$17.97-0.03(-0.17%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Caris Life Sciences, Inc.'s future dividend policy...
Alpha Chat Insight

Caris Life Sciences, Inc. trades at a P/E of -44.1 (undervalued) with modest ROE of 7.1%.

Ask for details

Company Overview

Caris Life Sciences, Inc. is a biotechnology company specializing in advanced molecular science and precision medicine, with a primary focus on cancer diagnostics and treatment. Founded in 2008 and headquartered in Irving, Texas, Caris develops and delivers innovative solutions that leverage genomic, proteomic, and transcriptomic analysis to improve patient outcomes by personalizing therapy selection and disease management. The company is renowned for its pioneering role in precision oncology, having built one of the largest integrated multimodal databases of matched molecular and clinical outcomes data worldwide, encompassing over half a million patient records. Through its proprietary molecular profiling technologies and AI-driven platforms, Caris empowers physicians with detailed, actionable insights, informing critical decisions in early disease detection, treatment optimization, and the development of next-generation therapies. The company’s initiatives extend beyond cancer, aiming to revolutionize healthcare and improve the human condition across various complex diseases. Caris also leads collaborative research through its Precision Oncology Alliance, partnering with top cancer centers to accelerate biomarker-driven innovation in medicine.

CEODr. David Dean Halbert M.D.
SectorHealthcare
IndustryBiotechnology
Employees1,769

Company Statistics

FY 2025

Profile

$3.00BMarket Cap
$812.03MRevenue
0.00Shares Out
1,769Employees

Margins

66.40%Gross
10.29%EBITDA
5.56%Operating
-8.38%Pre-Tax
-8.38%Net

Valuation

-44.13P/E
5.20P/B
3.70EV/Sales
31.55EV/EBITDA
44.92P/FCF

Growth (CAGR)

N/ARev 3Yr
22.53%Rev 5Yr
N/AOp Inc 3Yr
-10.26%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-9.27%ROA
7.09%ROE
-1.53%ROIC

Financial Health

$796.27MCash & Cash Equivalents
$-247.92MNet Debt
94.99%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Caris Life Sciences, Inc. (ticker: CAI) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 1,769 employees. Market cap is $3.0B.

The current price is $17.97 with a P/E ratio of -44.13x and P/B of 5.2x.

ROE is 7.09% and operating margin is 5.56%. Annual revenue is $812M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Caris Life Sciences, Inc. (CAI) Stock Forecast 2026 $17.97 — Price, Financials & Analyst Targets | Alpha Lenz